November 16th 2022 : Newsletter Upperton has made a significant investment in ASAPprime® software and hardware to enable the company to offer its clients state of the art stability testing. This exciting new platform can be used to generate robust, accelerated chemical stability data and is now being applied at all stages of the product … Read more
Successful nasal drug delivery of dry powder formulations requires a delivered dose that can penetrate beyond the nasal entrance region and deposit in the peripheral nasal cavity, whilst avoiding deeper penetration to the airways of the lungs. This delivery, or deposition pattern, is determined by the aerodynamic particle size of the powder exiting the device, … Read more
The Benefits of Powder Characterisation When developing products containing spray dried powders it is vital that the physical properties of the powders produced are determined. The physical properties of spray dried powders provides important information that can assist during the pre-formulation screening and early process development phases since these properties will have a direct impact … Read more
23rd May 2022 : Press Release Upperton Pharma Solutions (Upperton), a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a circa. £15m investment into the design and build of a 50,000 sq ft facility in Nottingham. The new facilities will allow a significant increase in research and development laboratory space and a 10-fold … Read more
21st April 2022 – Press Release Inflexion is pleased to announce it has made a substantial investment into Upperton Pharma Solutions (“Upperton”), a UK-based specialist contract development and manufacturing organisation (“CDMO”) which has expertise in particle engineering for the pharmaceutical industry. Inflexion has invested alongside the founder and the management team who will continue to … Read more
5th April 2022 – Press Release Nottingham-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions, has launched a unique nasal delivery development platform, UpperNose™, to make it easier and faster for small and mid-sized innovators to access the knowledge and capabilities necessary for the successful development of nasal dosage formulations. Drug developers seeking to … Read more
Nasal drug delivery route for small molecules and biologics. Recent trends have seen growing interest in exploiting nasal drug delivery as a means of delivering a wide range of drugs including small molecules and larger biologics for a wide range of indications. The nasal cavity is already a well-established delivery route capable of achieving rapid … Read more
20th May 2021 – Upperton Nasal Delivery Article Published in ONdrugDelivery Formulation Options In Nasal Drug Delivery Upperton had an article published in Edition 119 ONdrugDeliver in May 2021 In the article Richard Johnson, CEO and founder of Upperton, discusses the advantages of nasal delivery and why there is growing interest in this route of … Read more
Liquid Delivery Dry Powder Delivery Dry Powder vs Liquid Devices Delivery Considerations FAQs Talk to our experts Virtual Facility Tour Nasal delivery options The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous … Read more
Overview of Nasal Delivery Nasal Physiology for Drug Delivery Nasal Delivery Advantages FAQs Nasal Delivery Overview The anatomy and physiology of the nasal cavity creates a number of unique opportunities for the successful delivery of drugs and vaccines. This can be locally, systemically or directly to the central nervous system. This utility has resulted in … Read more
Driven by experts, led by science
Integrated CDMO services
By Development Stage
Development Platforms
Route of delivery
About Us
Our Approach
Events
Resources
Policies
Trent Gateway, Technology Drive, Beeston, Nottingham, NG9 1LA, UK. Phone: +44 (0) 115 855 7050 Email: contact@upperton.com
Copyright © 2025 Upperton Limited. Registration number: 03833301. Registered office address: Albert Einstein Centre, Nottingham Science Park, Nottingham, NG7 2TN. Registered in England. All rights reserved.
Speak with our team of experts and set up a discovery call to discuss your project in more detail.